RUBY-4: Povetacicept (ALPN-303) for Patients with Autoimmune Cytopenias
Condition: ITP, wAIHA, CAD
Sponsor: Alpine Immune Sciences, Inc.
Full Title
Protocol AIS-D04: A Phase 1b, Open-label Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Povetacicept in Subjects with Autoimmune Cytopenias
Study Treatment
Povetacicept (ALPN-303) is a dual BAFF/APRIL antagonist
Eligibility/Info
Primary immune thrombocytopenia, warm autoimmune hemolytic anemia, or cold agglutinin disease after failure of at least 2 treatment regimens.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
